NextCure Inc (NASDAQ:NXTC) saw a large drop in short interest in November. As of November 29th, there was short interest totalling 506,800 shares, a drop of 19.0% from the November 14th total of 625,500 shares. Based on an average daily trading volume, of 477,000 shares, the short-interest ratio is presently 1.1 days. Approximately 4.1% of the shares of the stock are short sold.

NextCure stock traded up $0.68 during trading hours on Friday, reaching $51.92. The company had a trading volume of 244,214 shares, compared to its average volume of 554,998. The company has a debt-to-equity ratio of 0.02, a current ratio of 15.00 and a quick ratio of 15.00. The company has a 50-day moving average price of $43.41 and a 200 day moving average price of $29.30. NextCure has a 12-month low of $13.86 and a 12-month high of $109.00.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.02). The business had revenue of $1.58 million during the quarter, compared to analyst estimates of $1.50 million. Analysts forecast that NextCure will post -2.19 EPS for the current year.

A number of equities analysts recently weighed in on the company. Morgan Stanley raised their price objective on NextCure from $33.00 to $52.00 and gave the company an “overweight” rating in a report on Wednesday, November 13th. Bank of America lifted their price target on NextCure from $27.00 to $44.00 and gave the stock a “buy” rating in a research note on Monday, September 9th. Zacks Investment Research cut NextCure from a “buy” rating to a “hold” rating in a research note on Tuesday, November 12th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $87.00 price target (down from $95.00) on shares of NextCure in a research note on Wednesday, November 20th. Finally, BTIG Research started coverage on NextCure in a research note on Tuesday, November 26th. They issued a “buy” rating and a $61.00 price target on the stock. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $57.50.

In other news, major shareholder Sofinnova Venture Partners Ix, acquired 150,000 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The shares were bought at an average cost of $36.75 per share, with a total value of $5,512,500.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link.

A number of institutional investors have recently made changes to their positions in the business. Squarepoint Ops LLC purchased a new position in NextCure in the 3rd quarter worth approximately $753,000. State Street Corp increased its stake in NextCure by 109.9% in the 3rd quarter. State Street Corp now owns 55,638 shares of the company’s stock worth $1,716,000 after purchasing an additional 29,136 shares during the period. Strs Ohio increased its stake in NextCure by 625.0% in the 3rd quarter. Strs Ohio now owns 5,800 shares of the company’s stock worth $178,000 after purchasing an additional 5,000 shares during the period. Orbimed Advisors LLC purchased a new position in NextCure in the 2nd quarter worth approximately $40,611,000. Finally, Victory Capital Management Inc. purchased a new position in shares of NextCure during the second quarter valued at approximately $48,000. 49.62% of the stock is currently owned by institutional investors and hedge funds.

About NextCure

There is no company description available for NextCure Inc

Further Reading: What is the Coverage Ratio?

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.